Research graph
References from CD84 Expression Across Disease Stages and Leukemic Subpopulations in Acute Myeloid Leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
10.1056/nejmoa1516192 · 2016 · External reference
The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data
10.1182/blood.2022015850 · 2022 · External reference
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: An Overview of Prevention and Treatment
10.1007/s12185-022-03416-7 · 2022 · External reference
Salvage Regimens Using Conventional Chemotherapy Agents for Relapsed/Refractory Adult AML Patients: A Systematic Literature Review
10.1007/s00277-018-3304-y · 2018 · External reference
Very Poor Long-term Survival in Past and More Recent Studies for Relapsed AML Patients: The ECOG-ACRIN Experience
10.1002/ajh.25162 · 2018 · External reference
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management
10.1002/ajh.27625 · 2025 · External reference
Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far
10.1038/s41571-023-00754-1 · 2023 · External reference
Results of ARI -0001 CART19 Cell Therapy in Patients with Relapsed/Refractory CD19 -positive Acute Lymphoblastic Leukemia with Isolated Extramedullary Disease
10.1002/ajh.26519 · 2022 · External reference
CAR-T Cell Therapy for Cancer: Current Challenges and Future Directions
10.1038/s41392-025-02269-w · 2025 · External reference
Honing CAR T Cells to Tackle Acute Myeloid Leukemia
10.1182/blood.2024024063 · 2025 · External reference
10.3390/curroncol32060322
10.3390/curroncol32060322 · External reference
10.3389/fimmu.2026.1863485
10.3389/fimmu.2026.1863485 · External reference
Exploring CAR Cell Therapies beyond CAR-T for Myeloid Malignancies
10.1186/s12929-026-01265-8 · 2026 · External reference
10.3389/fimmu.2023.1260470
10.3389/fimmu.2023.1260470 · External reference
CD123 Expression Levels in 846 Acute Leukemia Patients Based on Standardized Immunophenotyping
10.1002/cyto.b.21745 · 2019 · External reference
The Search for Safe and Effective CAR-T Targets in AML
10.1038/s41408-026-01544-5 · 2026 · External reference
CAR-T Cell Therapy for Treatment of Acute Myeloid Leukemia, Advances and Outcomes
10.1016/j.ymthe.2025.03.052 · 2025 · External reference
10.3389/fimmu.2026.1837609
10.3389/fimmu.2026.1837609 · External reference
CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
10.1097/hs9.0000000000000937 · 2023 · External reference
10.3389/fonc.2021.659253
10.3389/fonc.2021.659253 · External reference
CD84 Cell Surface Signaling Molecule: An Emerging Biomarker and Target for Cancer and Autoimmune Disorders
10.1016/j.clim.2018.10.017 · 2019 · External reference
A Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD84 for the Treatment of Acute Myeloid and T-Cell Lymphoblastic Leukemias
10.1038/s41375-025-02705-4 · 2025 · External reference
Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia
10.1182/blood-2022-166790 · 2022 · External reference
CD84 Is a Specific Target for Acute Myeloid Leukemia CAR-T Cell Therapy
10.1038/s41467-026-72361-4 · 2026 · External reference
Identification of CD84 as a Potent Survival Factor in Acute Myeloid Leukemia
10.1172/jci176818 · 2025 · External reference
EuroFlow Standardization of Flow Cytometer Instrument Settings and Immunophenotyping Protocols
10.1038/leu.2012.122 · 2012 · External reference
EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes
10.1038/leu.2012.120 · 2012 · External reference
Single Cell Multimodal Framework Identifies CD84 As a Leukaemic Stem Cell Target in Paediatric AML
10.1182/blood-2024-204084 · 2024 · External reference
Prognostic Impact of Immunophenotypic Classification for Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
10.1002/cyto.b.70016 · 2026 · External reference
Baseline Immunophenotypic Profile of Bone Marrow Leukemia Cells in Acute Myeloid Leukemia with Nucleophosmin-1 Gene Mutation: A EuroFlow Study
10.1038/s41408-023-00909-4 · 2023 · External reference
A Multimodal Atlas for Immunotherapeutic Targeting of AML Surface Heterogeneity
10.1016/j.isci.2026.115337 · 2026 · External reference
CD123 Expression and Its Correlation with Mutation Profile in Acute Myeloid Leukaemia
10.1111/bjh.70043 · 2025 · External reference
Very Poor Long-term Survival in Past and More Recent Studies for Relapsed AML Patients: The ECOG-ACRIN Experience
10.1002/ajh.25162 · ExternalCitation · doi-reference
Results of ARI -0001 CART19 Cell Therapy in Patients with Relapsed/Refractory CD19 -positive Acute Lymphoblastic Leukemia with Isolated Extramedullary Disease
10.1002/ajh.26519 · ExternalCitation · doi-reference
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management
10.1002/ajh.27625 · ExternalCitation · doi-reference
CD123 Expression Levels in 846 Acute Leukemia Patients Based on Standardized Immunophenotyping
10.1002/cyto.b.21745 · ExternalCitation · doi-reference
Prognostic Impact of Immunophenotypic Classification for Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
10.1002/cyto.b.70016 · ExternalCitation · doi-reference
Salvage Regimens Using Conventional Chemotherapy Agents for Relapsed/Refractory Adult AML Patients: A Systematic Literature Review
10.1007/s00277-018-3304-y · ExternalCitation · doi-reference
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: An Overview of Prevention and Treatment
10.1007/s12185-022-03416-7 · ExternalCitation · doi-reference
CD84 Cell Surface Signaling Molecule: An Emerging Biomarker and Target for Cancer and Autoimmune Disorders
10.1016/j.clim.2018.10.017 · ExternalCitation · doi-reference
A Multimodal Atlas for Immunotherapeutic Targeting of AML Surface Heterogeneity
10.1016/j.isci.2026.115337 · ExternalCitation · doi-reference
CAR-T Cell Therapy for Treatment of Acute Myeloid Leukemia, Advances and Outcomes
10.1016/j.ymthe.2025.03.052 · ExternalCitation · doi-reference
EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes
10.1038/leu.2012.120 · ExternalCitation · doi-reference
EuroFlow Standardization of Flow Cytometer Instrument Settings and Immunophenotyping Protocols
10.1038/leu.2012.122 · ExternalCitation · doi-reference
The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
10.1038/s41375-022-01613-1 · ExternalCitation · doi-reference
A Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD84 for the Treatment of Acute Myeloid and T-Cell Lymphoblastic Leukemias
10.1038/s41375-025-02705-4 · ExternalCitation · doi-reference
CAR-T Cell Therapy for Cancer: Current Challenges and Future Directions
10.1038/s41392-025-02269-w · ExternalCitation · doi-reference
Baseline Immunophenotypic Profile of Bone Marrow Leukemia Cells in Acute Myeloid Leukemia with Nucleophosmin-1 Gene Mutation: A EuroFlow Study
10.1038/s41408-023-00909-4 · ExternalCitation · doi-reference
The Search for Safe and Effective CAR-T Targets in AML
10.1038/s41408-026-01544-5 · ExternalCitation · doi-reference
CD84 Is a Specific Target for Acute Myeloid Leukemia CAR-T Cell Therapy
10.1038/s41467-026-72361-4 · ExternalCitation · doi-reference
Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far
10.1038/s41571-023-00754-1 · ExternalCitation · doi-reference
Genomic Classification and Prognosis in Acute Myeloid Leukemia
10.1056/nejmoa1516192 · ExternalCitation · doi-reference
CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
10.1097/hs9.0000000000000937 · ExternalCitation · doi-reference
CD123 Expression and Its Correlation with Mutation Profile in Acute Myeloid Leukaemia
10.1111/bjh.70043 · ExternalCitation · doi-reference
Identification of CD84 as a Potent Survival Factor in Acute Myeloid Leukemia
10.1172/jci176818 · ExternalCitation · doi-reference
Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia
10.1182/blood-2022-166790 · ExternalCitation · doi-reference
Single Cell Multimodal Framework Identifies CD84 As a Leukaemic Stem Cell Target in Paediatric AML
10.1182/blood-2024-204084 · ExternalCitation · doi-reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data
10.1182/blood.2022015850 · ExternalCitation · doi-reference
Honing CAR T Cells to Tackle Acute Myeloid Leukemia
10.1182/blood.2024024063 · ExternalCitation · doi-reference
Exploring CAR Cell Therapies beyond CAR-T for Myeloid Malignancies
10.1186/s12929-026-01265-8 · ExternalCitation · doi-reference
10.3389/fimmu.2023.1260470
10.3389/fimmu.2023.1260470 · ExternalCitation · doi-reference
10.3389/fimmu.2026.1837609
10.3389/fimmu.2026.1837609 · ExternalCitation · doi-reference
10.3389/fimmu.2026.1863485
10.3389/fimmu.2026.1863485 · ExternalCitation · doi-reference
10.3389/fonc.2021.659253
10.3389/fonc.2021.659253 · ExternalCitation · doi-reference
10.3390/curroncol32060322
10.3390/curroncol32060322 · ExternalCitation · doi-reference
